医药生物行业专题:海外制药企业2024Q4&全年业绩回顾

国信证券股份有...
07 Mar

创新品种放量依然是增长的主要驱动力。2024年,礼来及诺和诺德在GLP-1类药物驱动下,收入端分别+32%/+25%;阿斯利康在奥希替尼、达格列净等品种驱动下收入端+21%;辉瑞及安进分别受到收购并表Seagen及Horizon Therapeutics影响,收入端+12%(剔除新冠药物/ 疫苗) /+19%; 诺华、赛诺菲、Merck 分别依靠诺欣妥/ 可善挺、达必妥、K 药等核心产品驱动, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10